Urology
Volume 64, Issue 2 , Pages 311-315 , August 2004

uPM3, a new molecular urine test for the detection of prostate cancer

  • Yves Fradet

      Affiliations

    • Université Laval, Québec, Québec, Canada
    • Corresponding Author InformationReprint requests: Yves Fradet, M.D., Department of Surgery, Laval University, CHUQ – L'Hôtel-Dieu de Québec, 11 côte du Palais, Québec QB G1R 2J6, Canada
    • ,
  • Fred Saad

      Affiliations

    • Université de Montréal, Montréal, Québec, Canada
    • ,
  • Armen Aprikian

      Affiliations

    • McGill University, Montréal, Québec, Canada
    • ,
  • Jean Dessureault

      Affiliations

    • Université Laval, Québec, Québec, Canada
    • ,
  • Mostafa Elhilali

      Affiliations

    • McGill University, Montréal, Québec, Canada
    • ,
  • Claude Trudel

      Affiliations

    • Cité de la Santé, Laval, Québec, Canada
    • ,
  • Benoît Mâsse

      Affiliations

    • Fred Hutchinson Cancer Center, Seattle, Washington, USA
    • ,
  • Lyson Piché

      Affiliations

    • DiagnoCure Inc., Québec, Québec, Canada
    • ,
  • Camille Chypre

      Affiliations

    • DiagnoCure Inc., Québec, Québec, Canada

Received 6 November 2003 ,Accepted 24 March 2004.

References 

  1. Barry MJ. Prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377
  2. Harris R, Lohr KN. Screening for prostate cancer (an update of the evidence for the U.S. Preventive Services Task Force). Ann Intern Med. 2002;137:917–929
  3. Djavan B, Remzi M, Schulman CC, et al.  Repeat prostate biopsy (who, how, and when? A review). Eur Urol. 2002;42:93–103
  4. Babaian RJ, Johnston DA, Naccarato W, et al.  The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml (relation to biopsy strategy). J Urol. 2001;165:757–760
  5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination (enhancement of specificity with free PSA measurements). JAMA. 1997;277:1452–1455
  6. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, et al.  Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806–812
  7. De Koning HJ, Auvinen A, Berenguer Sanchez A, et al.  Large-scale randomized prostate cancer screening trials (program performances in the European Randomized Screening for Prostate Cancer Trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial). Int J Cancer. 2002;97:237–244
  8. Mikolajczyk SD, Marks LS, Partin AW, et al.  Free prostate-specific antigen in serum is becoming more complex. Urology. 2002;59:797–802
  9. Sokoll LJ, Chan DW, Mikolajczyk SD, et al.  Proenzyme PSA for the early detection of prostate cancer in the 2.5–4.0 ng/ml total PSA range (preliminary analysis). Urology. 2003;61:274–276
  10. Roehl KA, Antenor JAV, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol. 2002;168:922–925
  11. Goessl C, Müller M, Heicappell R, et al.  DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 2001;58:335–338
  12. Meid FH, Gygi CM, Leisinger HJ, et al.  The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol. 2001;165:1802–1805
  13. Hessels D, Klein Gunnewiek J, van Oort I, et al.  DD3PCA3 based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–16
  14. Bussemakers MJG, van Bokhoven A, Verhaegh GW, et al.  DD3 (a new prostate-specific gene, highly overexpressed in prostate cancer). Cancer Res. 1999;59:5975–5979
  15. de Kok JB, Verhaegh GW, Roelofs RW, et al.  DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–2698
  16. Boom R, Sol CJ, Salimans MM, et al.  Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495–503
  17. Malek L, Sooknanan R, Compton J. Nucleic acid sequence-based amplification (NASBA). Method Mol Biol. 1994;28:253–260
  18. Tan W, Fang X, Li J, et al.  Molecular beacons (a novel DNA probe for nucleic acid and protein studies). Chemistry. 2000;6:1107–1111
  19. Bostwick DG. High grade prostatic intraepithelial neoplasia (the most likely precursor of prostate cancer). Cancer. 1995;75:1823–1836
  20. Vis AN, Hoedemaeker RF, Roobol M, et al.  The predictive value of prostate cancer lesions that raise suspicion of concomitant carcinoma (an evaluation from a randomized, population-based study of screening for prostate cancer). Cancer. 2001;92:524–534
  21. Chan TY, Epstein JL. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology. 1999;53:351–355
  22. Goessl C, Krause H, Müller M, et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000;60:5941–5945
  23. Naughton CK, Miller DC, Mager DE, et al.  A prospective randomized trial comparing 6 versus 12 prostate biopsy cores (impact on cancer detection). J Urol. 2000;164:388–392

☆ Y. Fradet is also the Chief Scientific Officer for DiagnoCure Inc., which funded this trial. C. Chypre is the Director of Research & Development for DiagnoCure Inc.

PII: S0090-4295(04)00500-X

doi: 10.1016/j.urology.2004.03.052

Urology
Volume 64, Issue 2 , Pages 311-315 , August 2004

Article Tools

* Image Usage & Resolution